Dimensional Fund Advisors LP Has $1.25 Million Stake in Accuray Incorporated (NASDAQ:ARAY)

Dimensional Fund Advisors LP reduced its holdings in Accuray Incorporated (NASDAQ:ARAY - Free Report) by 28.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 634,066 shares of the medical equipment provider's stock after selling 253,451 shares during the quarter. Dimensional Fund Advisors LP owned about 0.62% of Accuray worth $1,254,000 as of its most recent filing with the SEC.

Several other institutional investors also recently added to or reduced their stakes in the business. Heartland Advisors Inc. raised its stake in Accuray by 14.1% during the 4th quarter. Heartland Advisors Inc. now owns 3,824,750 shares of the medical equipment provider's stock valued at $7,573,000 after purchasing an additional 472,800 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in Accuray by 482.4% in the 4th quarter. JPMorgan Chase & Co. now owns 242,713 shares of the medical equipment provider's stock valued at $481,000 after acquiring an additional 201,037 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Accuray by 6.8% in the 4th quarter. Renaissance Technologies LLC now owns 2,979,998 shares of the medical equipment provider's stock worth $5,900,000 after acquiring an additional 189,414 shares during the period. Walleye Capital LLC acquired a new stake in shares of Accuray during the 4th quarter worth approximately $300,000. Finally, Barclays PLC increased its position in shares of Accuray by 97.9% during the third quarter. Barclays PLC now owns 210,819 shares of the medical equipment provider's stock valued at $380,000 after purchasing an additional 104,310 shares during the period. 64.08% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, StockNews.com cut Accuray from a "buy" rating to a "hold" rating in a research report on Wednesday.

Accuray Stock Down 6.9%

Shares of ARAY opened at $1.62 on Thursday. The company has a quick ratio of 0.88, a current ratio of 1.62 and a debt-to-equity ratio of 3.51. The stock has a market cap of $166.88 million, a price-to-earnings ratio of -32.40 and a beta of 1.30. Accuray Incorporated has a 12 month low of $1.28 and a 12 month high of $2.95. The company has a 50-day moving average price of $1.61 and a two-hundred day moving average price of $1.90.

Accuray (NASDAQ:ARAY - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The medical equipment provider reported ($0.01) EPS for the quarter, beating analysts' consensus estimates of ($0.05) by $0.04. The firm had revenue of $113.24 million for the quarter, compared to analyst estimates of $101.53 million. Accuray had a negative net margin of 0.96% and a negative return on equity of 9.75%. Equities analysts predict that Accuray Incorporated will post 0.01 EPS for the current fiscal year.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.